Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 28, 2021

Ribociclib Plus Fulvestrant for Postmenopausal Women With HR+/HER2− Advanced Breast Cancer

Annals of Oncology


Additional Info

Annals of Oncology
Ribociclib Plus Fulvestrant for Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the Phase 3 Randomized MONALEESA-3 Trial: Updated Overall Survival
Ann. Oncol 2021 Jun 05;[EPub Ahead of Print], DJ Slamon, P Neven, S Chia, G Jerusalem, M De Laurentiis, S Im, K Petrakova, GV Bianchi, M Martín, A Nusch, GS Sonke, L De la Cruz-Merino, JT Beck, Y Ji, C Wang, U Deore, A Chakravartty, JP Zarate, T Taran, PA Fasching

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading